Results 151 to 160 of about 74,157 (302)

Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer [PDF]

, 2017
Chen, Ina, et al,
core   +2 more sources

Combining radiotherapy with CAR‐T cell therapy for solid tumors: Challenges, mechanisms, and future directions

Precision Radiation Oncology, EarlyView.
Radiotherapy enhances CAR‐Tcell therapy by increasing antigenicity, improving trafficking, and reshaping the tumor microenvironment. Despite its dual effects, including potential immune suppression, understanding these mechanisms enables the development of strategies to maximize synergy in solid tumors.
Leran Qiu, Xingyu Zhou, Jiao Xue, Xiaokang Zhang, Songbing Qin   +4 more
wiley   +1 more source

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis

Journal of Inflammation Research, 2013
Maurizio Cutolo, Marianna Meroni Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Abstract: Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected ...
Cutolo M, Meroni M
doaj  

Advances in mucosal injury mechanisms in radiation‐induced esophagitis associated with thoracic radiotherapy

Precision Radiation Oncology, EarlyView.
There is no specific therapeutic drug regimen for radiation esophagitis. In previous studies, radiation esophagitis was considered a self‐limiting disease; however, current clinical approaches are limited to symptomatic treatment, which yields unsatisfactory therapeutic outcomes.
Hao Zhang, Liangxue Luo, Chaofen Zhao, Bibo Wu, Jing Zhang, Lingfeng Liu, Bing Lu, Shengfa Su   +7 more
wiley   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation–Energy Axis?

Phytotherapy Research, EarlyView.
ABSTRACT Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by a preclinical stage that typically lasts for decades. Early on during this time, microglia react to pathological changes and become protective and even transiently delay neurodegeneration.
Sara Merlo, Cristiana Lucia Rita Lipari, Aurora Patti, Maria Angela Sortino   +3 more
wiley   +1 more source

Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells [PDF]

, 2015
Barnes, PJ, Donnelly, LE, Fenwick, PS, Macedo, P   +3 more
core   +1 more source

Flavonoids in Nasal Therapeutics: Biological Activities, Delivery Challenges, and Formulation Strategies–A Systematic Review

Phytotherapy Research, EarlyView.
Overview of the therapeutic potential of flavonoids in nasal delivery systems, highlighting their benefits to the human nasal cavity, and applications in the treatment of respiratory and brain‐related diseases. ABSTRACT Flavonoids represent a significant group of secondary metabolites.
Jeniffer Viviana Ramirez Hernández, Sara Elis Bianchi, Flávia Nathiely Silveira Fachel, Elizandra Braganhol, Sheila Porto de Matos, Valquíria Linck Bassani   +5 more
wiley   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

Rheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama, Saki Okuda‐Tsuchimoto, Takashi tsuchimoto, Koji Kinoshita, Itaru Matsumura   +4 more
wiley   +1 more source